Oculis Reports Q1 2024 Financial Results and Provides Company Updates
The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
- The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
- Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
Snehal Shah, Pharm. - The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
- The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.